DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir

Information source: Radboud University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Varicella Zoster Virus Infection; Herpes Simplex Virus Infection

Intervention: valacyclovir tablet (Drug); valacyclovir oral solution (Drug)

Phase: Phase 1

Status: Suspended

Sponsored by: Radboud University

Official(s) and/or principal investigator(s):
Bas Schouwenberg, MD, Principal Investigator, Affiliation: Radboud University


A new paediatric formulation (oral liquid) has been developed for flexible and accurate dosing of valacyclovir in children. To establish the bioavailability of this new formulation, healthy volunteers will be exposed to the new formulation and to valacyclovir tablets. The concentration of valacyclovir in their blood after exposure to the oral liquid will be measured and compared to the tablet.

Clinical Details

Official title: Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir Used for Prophylaxis and Treatment of VZV and HSV Infections in Children, Phase I (VALID-I)

Study design: Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Primary outcome: Geometric Mean Ratios and 90% confidence intervals of pharmacokinetic parameters of acyclovir taken as valacyclovir tablet or oral solution

Secondary outcome: Determine the safety profile of a single dose of valacyclovir oral solution

Detailed description: Bioequivalence of the new valcyclovir formulation will be tested according to the EMA guideline for bioequivalence.


Minimum age: 18 Years. Maximum age: 55 Years. Gender(s): Both.


Inclusion Criteria:

- Subject is at least 18 and not older than 55 years of age at screening.

- Subject does not smoke more than 10 cigarettes, 2 cigars, or 2 pipes per day for at

least 3 months prior to the first dosing

- Subject has a Quetelet Index (Body Mass Index) of 18 to 30 kg/m2, extremes included.

- Subject has signed the Informed Consent Form prior to screening evaluations.

- Subject is in good age-appropriate health condition as established by medical

history, physical examination, electrocardiography, results of biochemistry, haematology and urinalysis testing within 4 weeks prior to the first dose. Results of biochemistry, haematology and urinalysis testing should be within the laboratory's reference ranges (see Appendix A). If laboratory results are not within the reference ranges, the subject is included on condition that the investigator judges that the deviations are not clinically relevant. This should be clearly recorded.

- Subject has a normal blood pressure and pulse rate, according to the investigator's


- Female subject is either not of childbearing potential, defined as postmenopausal for

at least 1 year or is of childbearing potential with adequate contraception (e. g. hysterectomy, bilateral tubal ligation, (nonhormonal) intrauterine device, total abstinence, double barrier methods, vasectomized partner). Exclusion Criteria:

- Documented history of sensitivity/idiosyncrasy to medicinal products or excipients.

- Positive HIV, hepatitis B or C test.

- Therapy with any drug (for two weeks preceding dosing), except for acetaminophen.

- Relevant history or presence of pulmonary disorders (especially COPD), cardiovascular

disorders, neurological disorders (especially seizures and migraine), gastro-intestinal disorders, renal and hepatic disorders, hormonal disorders (especially diabetes mellitus), coagulation disorders.

- Relevant history or current condition that might interfere with drug absorption,

distribution, metabolism or excretion.

- History of or current abuse of drugs, alcohol or solvents.

- Inability to understand the nature and extent of the trial and the procedures


- Participation in a drug trial within 60 days prior to the first dose.

- Donation of blood within 60 days prior to the first dose.

- Febrile illness within 3 days before the first dose.

- Pregnant female (as confirmed by an HCG test performed less than 4 weeks before the

first dose) or breast-feeding female.

Locations and Contacts

Radboud University Medical Center, Nijmegen, Netherlands
Additional Information

Starting date: December 2013
Last updated: September 29, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017